Cargando…
Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug
Tamoxifen is a drug that has been in worldwide use for the treatment of estrogen receptor (ER)-positive breast cancer for over 30 years; it has been used in both the metastatic and adjuvant settings. Tamoxifen's approval for breast cancer risk reduction dates back to 1998, after results from th...
Autores principales: | Lazzeroni, Matteo, Serrano, Davide, Dunn, Barbara K, Heckman-Stoddard, Brandy M, Lee, Oukseub, Khan, Seema, Decensi, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053098/ https://www.ncbi.nlm.nih.gov/pubmed/23106852 http://dx.doi.org/10.1186/bcr3233 |
Ejemplares similares
-
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia
por: DeCensi, Andrea, et al.
Publicado: (2019) -
A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer
por: Serrano, Davide, et al.
Publicado: (2013) -
Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial
por: DeCensi, Andrea, et al.
Publicado: (2021) -
Metabolic Surgery and Cancer Risk: An Opportunity for Mechanistic Research
por: Sauter, Edward R., et al.
Publicado: (2021) -
Tamoxifen reduces plasma homocysteine levels in healthy women.
por: Cattaneo, M., et al.
Publicado: (1998)